Deciphera Pharmaceuticals, Inc. (DCPH)
DCPH moved a median of +0.04% 30 minutes after news, and -0.04% by the close. How DCPH actually reacts to news — the realized, point-in-time move the market made, measured across 129 labeled events over the last three years with zero look-ahead.
DCPH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 98 |
| 30-min | +0.04% | 55% | 98 |
| 60-min | +0.02% | 52% | 98 |
| to close | -0.04% | 45% | 98 |
| Middle 50% of DCPH reactions | -0.32% to +0.56% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 129 |
Half of all Deciphera Pharmaceuticals, Inc. news events land between -0.32% and +0.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DCPH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.01% | 50% | -2.56% |
| Analyst downgrades | 12 | +0.07% | 67% | +0.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how DCPH ranks against every other measured name →
That’s how DCPH usually reacts — get an email when it moves on news →Email me when DCPH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DCPH's baseline. Nothing else.
Recent DCPH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Deciphera Pharmaceutical | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Deciphera Pharmaceutical | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Deciphera Pharmaceutical For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Deciphera Pharmaceutical | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR Deciphera Pharmaceutical | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Deciphera Pharmaceutical | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | Press release | PR Newswire | — | — | |
| Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet | Press release | Business Wire | +0.00% | +0.04% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH) | Press release | GlobeNewswire | +0.00% | +0.00% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH | Press release | PR Newswire | +0.00% | +0.00% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH | Press release | PR Newswire | -0.08% | +0.00% | |
| Form 10-Q Deciphera Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.16% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, DPSI, UNIT | Press release | GlobeNewswire | -0.04% | -0.04% | |
| Lifshitz Law PLLC Announces Investigations of DCPH, SLCA, HCP, and HTLF | Press release | Accesswire | -0.04% | -0.04% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK | Press release | PR Newswire | -0.02% | -0.04% | |
| ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals | Press release | PR Newswire | +0.20% | +0.16% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, UMBF, TBNK | Press release | Accesswire | +0.00% | -0.28% | |
| DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.12% | +0.32% | |
| Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion | Press release | Business Wire | +0.12% | +0.32% | |
| Form 8-K Deciphera Pharmaceutical For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +0.32% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, HCP | Press release | GlobeNewswire | +0.20% | +0.16% | |
| SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates DCPH, HTLF, UMBF, HCP | Press release | PR Newswire | +0.08% | +0.24% | |
| Form ARS Deciphera Pharmaceutical For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.77% | +3.10% | |
| Form DEF 14A Deciphera Pharmaceutical For: Jun 20 | SEC filing · Form DEF | SEC EDGAR | -0.69% | -1.73% | |
| Form DEFA14A Deciphera Pharmaceutical | SEC filing · Form DEFA14A | SEC EDGAR | +0.77% | +3.10% | |
| Form PRER14A Deciphera Pharmaceutical | SEC filing · Form PRER14A | SEC EDGAR | +0.00% | -1.42% | |
| Form PRE 14A Deciphera Pharmaceutical For: Jun 20 | SEC filing · Form PRE | SEC EDGAR | -0.76% | -1.83% | |
| Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum | Press release | Business Wire | -0.03% | +3.78% | |
| Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.72% | +2.17% | |
| Form 10-K Deciphera Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.34% | -5.97% | |
| Form S-8 Deciphera Pharmaceutical | SEC filing · Form S-8 | SEC EDGAR | -1.34% | -5.97% | |
| Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results | Press release | Business Wire | -4.36% | -0.60% | |
| Form 8-K Deciphera Pharmaceutical For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -4.36% | -0.60% | |
| Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 | Press release | Business Wire | -0.28% | -0.28% | |
| Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | Press release | Business Wire | -0.17% | +3.00% | |
| Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | Press release | Business Wire | +0.43% | -0.14% | |
| GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe | Press release | Business Wire | +0.26% | -2.05% | |
| Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company | Press release | Business Wire | -1.43% | +1.68% | |
| Form 8-K Deciphera Pharmaceutical For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | +1.68% | |
| Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 | Press release | Business Wire | -3.80% | -3.23% | |
| Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.28% | +3.57% | |
| Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit | Press release | Business Wire | +1.30% | +0.98% | |
| Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.70% | -1.81% | |
| Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT | Press release | Business Wire | -1.88% | +4.56% | |
| Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results | Press release | Business Wire | -1.88% | +4.56% | |
| Form 10-Q Deciphera Pharmaceutical For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.88% | +4.56% | |
| Form 8-K Deciphera Pharmaceutical For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | +4.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DCPH section they belong to.
Where else DCPH is measured.
DCPH earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | 130 | +0.20% | 53% |
| INNATE PHARMA (IPHYF) | 130 | 0.00% | 0% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 129 | -0.18% | 44% |
| Medicenna Therapeutics Corp (MDNA_TSE) | 127 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Deciphera Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled DCPH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 129 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of DCPH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DCPH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.